Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.21 CAD | +10.53% |
|
+13.51% | +20.00% |
06-20 | Theralase Technologies Inc. Announces Rutherrin Repurposes Non-Cancer Drugs for Cancer Therapy | CI |
06-12 | Theralase Technologies Inc. Announces Rutherrin Increases Efficacy of Chemotherapy | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.00% | 36.72M | |
-4.26% | 810M | |
-31.56% | 216M | |
-.--% | 121M | |
-26.78% | 84.74M | |
+0.51% | 55.64M |
- Stock Market
- Equities
- TLT Stock
- News Theralase Technologies Inc.
- Theralase Re-appointed Founder Roger DuMoulin-White as President and CEO As OSC Order Has Expired